This approach heralds a novel avenue for gene therapy in oncology.488 Pothuraju and colleagues tackled the role of MUC5AC, a secretory mucin whose dysregulation is implicated in both the progression of colon cancer and the emergence of chemoresistance. Here, MUC5AC is linked to malignant colon neoplasm.